nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—BMPR2—breast cancer	0.432	0.93	CbGaD
Ruxolitinib—CYP3A4—breast cancer	0.0325	0.07	CbGaD
Ruxolitinib—CYP3A4—Exemestane—breast cancer	0.0102	0.133	CbGbCtD
Ruxolitinib—CYP3A4—Letrozole—breast cancer	0.00863	0.113	CbGbCtD
Ruxolitinib—CYP3A4—Anastrozole—breast cancer	0.00769	0.101	CbGbCtD
Ruxolitinib—CYP3A4—Toremifene—breast cancer	0.00704	0.0921	CbGbCtD
Ruxolitinib—CYP3A4—Fulvestrant—breast cancer	0.00654	0.0856	CbGbCtD
Ruxolitinib—CYP3A4—Thiotepa—breast cancer	0.00583	0.0763	CbGbCtD
Ruxolitinib—CYP3A4—Ixabepilone—breast cancer	0.00533	0.0698	CbGbCtD
Ruxolitinib—CYP3A4—Lapatinib—breast cancer	0.00513	0.0672	CbGbCtD
Ruxolitinib—CYP3A4—Raloxifene—breast cancer	0.00389	0.0509	CbGbCtD
Ruxolitinib—CYP3A4—Vinorelbine—breast cancer	0.00285	0.0373	CbGbCtD
Ruxolitinib—CYP3A4—Tamoxifen—breast cancer	0.00257	0.0336	CbGbCtD
Ruxolitinib—CYP3A4—Mitoxantrone—breast cancer	0.00251	0.0328	CbGbCtD
Ruxolitinib—CYP3A4—Paclitaxel—breast cancer	0.002	0.0262	CbGbCtD
Ruxolitinib—CYP3A4—Irinotecan—breast cancer	0.00197	0.0258	CbGbCtD
Ruxolitinib—CYP3A4—Vinblastine—breast cancer	0.00175	0.023	CbGbCtD
Ruxolitinib—CYP3A4—Docetaxel—breast cancer	0.00145	0.0189	CbGbCtD
Ruxolitinib—CYP3A4—Doxorubicin—breast cancer	0.00108	0.0141	CbGbCtD
Ruxolitinib—JAK1—epithelium—breast cancer	0.000554	0.00483	CbGeAlD
Ruxolitinib—CAMK1—pituitary gland—breast cancer	0.000548	0.00477	CbGeAlD
Ruxolitinib—CAMK1—adipose tissue—breast cancer	0.000546	0.00475	CbGeAlD
Ruxolitinib—TYK2—nipple—breast cancer	0.000544	0.00474	CbGeAlD
Ruxolitinib—RPS6KA6—endocrine gland—breast cancer	0.000544	0.00474	CbGeAlD
Ruxolitinib—PLK1—endocrine gland—breast cancer	0.000544	0.00474	CbGeAlD
Ruxolitinib—MKNK2—nipple—breast cancer	0.000537	0.00468	CbGeAlD
Ruxolitinib—PLK3—female reproductive system—breast cancer	0.000536	0.00467	CbGeAlD
Ruxolitinib—MARK2—adipose tissue—breast cancer	0.00053	0.00462	CbGeAlD
Ruxolitinib—JAK1—skin of body—breast cancer	0.000527	0.00459	CbGeAlD
Ruxolitinib—PLK3—adrenal gland—breast cancer	0.000523	0.00456	CbGeAlD
Ruxolitinib—LTK—female reproductive system—breast cancer	0.000518	0.00451	CbGeAlD
Ruxolitinib—CAMK1—female reproductive system—breast cancer	0.000502	0.00437	CbGeAlD
Ruxolitinib—JAK1—endometrium—breast cancer	0.000497	0.00433	CbGeAlD
Ruxolitinib—JAK2—nipple—breast cancer	0.000495	0.00431	CbGeAlD
Ruxolitinib—TAOK2—pituitary gland—breast cancer	0.000492	0.00429	CbGeAlD
Ruxolitinib—TAOK2—adipose tissue—breast cancer	0.00049	0.00427	CbGeAlD
Ruxolitinib—CAMK1—adrenal gland—breast cancer	0.00049	0.00426	CbGeAlD
Ruxolitinib—PLK3—female gonad—breast cancer	0.000488	0.00425	CbGeAlD
Ruxolitinib—MARK2—female reproductive system—breast cancer	0.000487	0.00424	CbGeAlD
Ruxolitinib—MAP3K3—nipple—breast cancer	0.000477	0.00416	CbGeAlD
Ruxolitinib—ROCK1—epithelium—breast cancer	0.000477	0.00416	CbGeAlD
Ruxolitinib—MARK2—adrenal gland—breast cancer	0.000475	0.00414	CbGeAlD
Ruxolitinib—DAPK2—endometrium—breast cancer	0.000474	0.00413	CbGeAlD
Ruxolitinib—JAK1—uterus—breast cancer	0.000458	0.00399	CbGeAlD
Ruxolitinib—DCLK1—uterus—breast cancer	0.000458	0.00399	CbGeAlD
Ruxolitinib—CAMK1—female gonad—breast cancer	0.000457	0.00398	CbGeAlD
Ruxolitinib—PLK3—endocrine gland—breast cancer	0.000454	0.00395	CbGeAlD
Ruxolitinib—JAK3—adipose tissue—breast cancer	0.000451	0.00392	CbGeAlD
Ruxolitinib—DCLK1—pituitary gland—breast cancer	0.00045	0.00392	CbGeAlD
Ruxolitinib—JAK1—pituitary gland—breast cancer	0.00045	0.00392	CbGeAlD
Ruxolitinib—JAK1—adipose tissue—breast cancer	0.000448	0.0039	CbGeAlD
Ruxolitinib—DCLK1—adipose tissue—breast cancer	0.000448	0.0039	CbGeAlD
Ruxolitinib—PLK1—Chlorambucil—Melphalan—breast cancer	0.000448	0.114	CbGdCrCtD
Ruxolitinib—DAPK3—endometrium—breast cancer	0.000446	0.00388	CbGeAlD
Ruxolitinib—CLK2—endometrium—breast cancer	0.000441	0.00384	CbGeAlD
Ruxolitinib—BMPR2—skin of body—breast cancer	0.000441	0.00384	CbGeAlD
Ruxolitinib—TAOK2—adrenal gland—breast cancer	0.00044	0.00383	CbGeAlD
Ruxolitinib—CAMK1D—pituitary gland—breast cancer	0.000439	0.00382	CbGeAlD
Ruxolitinib—CAMK1D—adipose tissue—breast cancer	0.000437	0.00381	CbGeAlD
Ruxolitinib—TAOK3—nipple—breast cancer	0.000435	0.00379	CbGeAlD
Ruxolitinib—PHKG2—adipose tissue—breast cancer	0.000434	0.00378	CbGeAlD
Ruxolitinib—RET—embryo—breast cancer	0.000432	0.00376	CbGeAlD
Ruxolitinib—DAPK2—adipose tissue—breast cancer	0.000427	0.00372	CbGeAlD
Ruxolitinib—CAMK1—endocrine gland—breast cancer	0.000425	0.0037	CbGeAlD
Ruxolitinib—STK16—pituitary gland—breast cancer	0.000422	0.00368	CbGeAlD
Ruxolitinib—STK16—adipose tissue—breast cancer	0.00042	0.00366	CbGeAlD
Ruxolitinib—HIPK2—adipose tissue—breast cancer	0.000418	0.00364	CbGeAlD
Ruxolitinib—JAK3—female reproductive system—breast cancer	0.000414	0.00361	CbGeAlD
Ruxolitinib—MARK2—endocrine gland—breast cancer	0.000412	0.00359	CbGeAlD
Ruxolitinib—JAK1—female reproductive system—breast cancer	0.000412	0.00358	CbGeAlD
Ruxolitinib—DAPK3—uterus—breast cancer	0.000411	0.00358	CbGeAlD
Ruxolitinib—TAOK2—female gonad—breast cancer	0.00041	0.00357	CbGeAlD
Ruxolitinib—PLK4—female reproductive system—breast cancer	0.000409	0.00356	CbGeAlD
Ruxolitinib—JAK2—embryo—breast cancer	0.000408	0.00356	CbGeAlD
Ruxolitinib—JAK3—adrenal gland—breast cancer	0.000404	0.00352	CbGeAlD
Ruxolitinib—DAPK3—pituitary gland—breast cancer	0.000403	0.00351	CbGeAlD
Ruxolitinib—JAK1—adrenal gland—breast cancer	0.000402	0.0035	CbGeAlD
Ruxolitinib—DCLK1—adrenal gland—breast cancer	0.000402	0.0035	CbGeAlD
Ruxolitinib—DAPK3—adipose tissue—breast cancer	0.000402	0.0035	CbGeAlD
Ruxolitinib—CLK2—pituitary gland—breast cancer	0.000399	0.00348	CbGeAlD
Ruxolitinib—PHKG2—female reproductive system—breast cancer	0.000399	0.00348	CbGeAlD
Ruxolitinib—PLK4—adrenal gland—breast cancer	0.000399	0.00348	CbGeAlD
Ruxolitinib—CLK2—adipose tissue—breast cancer	0.000398	0.00347	CbGeAlD
Ruxolitinib—NUAK2—endometrium—breast cancer	0.000397	0.00346	CbGeAlD
Ruxolitinib—CAMK1D—adrenal gland—breast cancer	0.000392	0.00341	CbGeAlD
Ruxolitinib—PRKCE—lymph node—breast cancer	0.000391	0.00341	CbGeAlD
Ruxolitinib—PHKG2—adrenal gland—breast cancer	0.00039	0.00339	CbGeAlD
Ruxolitinib—JAK1—bone marrow—breast cancer	0.000389	0.00338	CbGeAlD
Ruxolitinib—STK16—female reproductive system—breast cancer	0.000386	0.00336	CbGeAlD
Ruxolitinib—PLK4—bone marrow—breast cancer	0.000386	0.00336	CbGeAlD
Ruxolitinib—HIPK2—female reproductive system—breast cancer	0.000384	0.00335	CbGeAlD
Ruxolitinib—DAPK2—adrenal gland—breast cancer	0.000383	0.00334	CbGeAlD
Ruxolitinib—BMPR2—uterus—breast cancer	0.000383	0.00334	CbGeAlD
Ruxolitinib—DYRK1A—Topotecan—Irinotecan—breast cancer	0.000378	0.0966	CbGdCrCtD
Ruxolitinib—STK16—adrenal gland—breast cancer	0.000377	0.00328	CbGeAlD
Ruxolitinib—JAK3—female gonad—breast cancer	0.000377	0.00328	CbGeAlD
Ruxolitinib—MAP3K19—female reproductive system—breast cancer	0.000376	0.00328	CbGeAlD
Ruxolitinib—BMPR2—pituitary gland—breast cancer	0.000376	0.00328	CbGeAlD
Ruxolitinib—DYRK1A—adipose tissue—breast cancer	0.000376	0.00328	CbGeAlD
Ruxolitinib—PLK1—lymph node—breast cancer	0.000376	0.00327	CbGeAlD
Ruxolitinib—RPS6KA6—lymph node—breast cancer	0.000376	0.00327	CbGeAlD
Ruxolitinib—HIPK2—adrenal gland—breast cancer	0.000375	0.00327	CbGeAlD
Ruxolitinib—BMPR2—adipose tissue—breast cancer	0.000375	0.00326	CbGeAlD
Ruxolitinib—JAK1—female gonad—breast cancer	0.000374	0.00326	CbGeAlD
Ruxolitinib—CAMK2G—endometrium—breast cancer	0.000372	0.00324	CbGeAlD
Ruxolitinib—BMP2K—endometrium—breast cancer	0.000372	0.00324	CbGeAlD
Ruxolitinib—DAPK2—bone marrow—breast cancer	0.000371	0.00323	CbGeAlD
Ruxolitinib—DAPK3—female reproductive system—breast cancer	0.000369	0.00322	CbGeAlD
Ruxolitinib—LRRK2—endometrium—breast cancer	0.000369	0.00321	CbGeAlD
Ruxolitinib—CLK2—female reproductive system—breast cancer	0.000366	0.00319	CbGeAlD
Ruxolitinib—CAMK1D—female gonad—breast cancer	0.000365	0.00318	CbGeAlD
Ruxolitinib—PHKG2—female gonad—breast cancer	0.000363	0.00317	CbGeAlD
Ruxolitinib—MKNK2—epithelium—breast cancer	0.000362	0.00315	CbGeAlD
Ruxolitinib—DAPK3—adrenal gland—breast cancer	0.00036	0.00314	CbGeAlD
Ruxolitinib—NUAK2—pituitary gland—breast cancer	0.000359	0.00313	CbGeAlD
Ruxolitinib—NUAK2—adipose tissue—breast cancer	0.000358	0.00312	CbGeAlD
Ruxolitinib—DAPK2—female gonad—breast cancer	0.000357	0.00311	CbGeAlD
Ruxolitinib—CLK2—adrenal gland—breast cancer	0.000357	0.00311	CbGeAlD
Ruxolitinib—ROCK1—female reproductive system—breast cancer	0.000354	0.00309	CbGeAlD
Ruxolitinib—RET—epithelium—breast cancer	0.000353	0.00307	CbGeAlD
Ruxolitinib—STK16—female gonad—breast cancer	0.000351	0.00306	CbGeAlD
Ruxolitinib—JAK3—endocrine gland—breast cancer	0.00035	0.00305	CbGeAlD
Ruxolitinib—HIPK2—female gonad—breast cancer	0.00035	0.00305	CbGeAlD
Ruxolitinib—TYK2—skin of body—breast cancer	0.000348	0.00303	CbGeAlD
Ruxolitinib—JAK1—endocrine gland—breast cancer	0.000348	0.00303	CbGeAlD
Ruxolitinib—DCLK1—endocrine gland—breast cancer	0.000348	0.00303	CbGeAlD
Ruxolitinib—PLK4—endocrine gland—breast cancer	0.000346	0.00301	CbGeAlD
Ruxolitinib—DYRK1A—female reproductive system—breast cancer	0.000346	0.00301	CbGeAlD
Ruxolitinib—CLK2—bone marrow—breast cancer	0.000345	0.00301	CbGeAlD
Ruxolitinib—BMPR2—female reproductive system—breast cancer	0.000344	0.003	CbGeAlD
Ruxolitinib—CAMK2G—uterus—breast cancer	0.000343	0.00299	CbGeAlD
Ruxolitinib—CAMK1D—endocrine gland—breast cancer	0.00034	0.00296	CbGeAlD
Ruxolitinib—PHKG2—endocrine gland—breast cancer	0.000338	0.00294	CbGeAlD
Ruxolitinib—DYRK1A—adrenal gland—breast cancer	0.000337	0.00294	CbGeAlD
Ruxolitinib—CAMK2G—pituitary gland—breast cancer	0.000337	0.00293	CbGeAlD
Ruxolitinib—BMPR2—adrenal gland—breast cancer	0.000336	0.00293	CbGeAlD
Ruxolitinib—DAPK3—female gonad—breast cancer	0.000336	0.00293	CbGeAlD
Ruxolitinib—CAMK2G—adipose tissue—breast cancer	0.000335	0.00292	CbGeAlD
Ruxolitinib—BMP2K—adipose tissue—breast cancer	0.000335	0.00292	CbGeAlD
Ruxolitinib—MAP3K7—endometrium—breast cancer	0.000335	0.00291	CbGeAlD
Ruxolitinib—LRRK2—pituitary gland—breast cancer	0.000334	0.00291	CbGeAlD
Ruxolitinib—JAK2—epithelium—breast cancer	0.000333	0.0029	CbGeAlD
Ruxolitinib—CLK2—female gonad—breast cancer	0.000333	0.0029	CbGeAlD
Ruxolitinib—LRRK2—adipose tissue—breast cancer	0.000332	0.00289	CbGeAlD
Ruxolitinib—TYK2—endometrium—breast cancer	0.000328	0.00286	CbGeAlD
Ruxolitinib—STK16—endocrine gland—breast cancer	0.000327	0.00285	CbGeAlD
Ruxolitinib—HIPK2—endocrine gland—breast cancer	0.000325	0.00283	CbGeAlD
Ruxolitinib—MKNK2—endometrium—breast cancer	0.000324	0.00282	CbGeAlD
Ruxolitinib—ROCK1—female gonad—breast cancer	0.000322	0.00281	CbGeAlD
Ruxolitinib—NUAK2—adrenal gland—breast cancer	0.000321	0.0028	CbGeAlD
Ruxolitinib—JAK2—skin of body—breast cancer	0.000317	0.00276	CbGeAlD
Ruxolitinib—DYRK1A—female gonad—breast cancer	0.000315	0.00274	CbGeAlD
Ruxolitinib—PLK3—lymph node—breast cancer	0.000314	0.00273	CbGeAlD
Ruxolitinib—BMPR2—female gonad—breast cancer	0.000313	0.00273	CbGeAlD
Ruxolitinib—DAPK3—endocrine gland—breast cancer	0.000312	0.00272	CbGeAlD
Ruxolitinib—MAP3K2—uterus—breast cancer	0.000311	0.00271	CbGeAlD
Ruxolitinib—NUAK2—bone marrow—breast cancer	0.000311	0.00271	CbGeAlD
Ruxolitinib—CLK2—endocrine gland—breast cancer	0.000309	0.0027	CbGeAlD
Ruxolitinib—MAP3K7—uterus—breast cancer	0.000308	0.00269	CbGeAlD
Ruxolitinib—BMP2K—female reproductive system—breast cancer	0.000308	0.00268	CbGeAlD
Ruxolitinib—CAMK2G—female reproductive system—breast cancer	0.000308	0.00268	CbGeAlD
Ruxolitinib—MAP3K3—skin of body—breast cancer	0.000306	0.00266	CbGeAlD
Ruxolitinib—LRRK2—female reproductive system—breast cancer	0.000305	0.00266	CbGeAlD
Ruxolitinib—MAP3K2—adipose tissue—breast cancer	0.000304	0.00265	CbGeAlD
Ruxolitinib—LTK—lymph node—breast cancer	0.000303	0.00264	CbGeAlD
Ruxolitinib—MAP3K7—pituitary gland—breast cancer	0.000303	0.00264	CbGeAlD
Ruxolitinib—TYK2—uterus—breast cancer	0.000303	0.00264	CbGeAlD
Ruxolitinib—MAP3K7—adipose tissue—breast cancer	0.000301	0.00263	CbGeAlD
Ruxolitinib—CAMK2G—adrenal gland—breast cancer	0.000301	0.00262	CbGeAlD
Ruxolitinib—BMP2K—adrenal gland—breast cancer	0.000301	0.00262	CbGeAlD
Ruxolitinib—ROCK1—endocrine gland—breast cancer	0.0003	0.00261	CbGeAlD
Ruxolitinib—NUAK2—female gonad—breast cancer	0.000299	0.00261	CbGeAlD
Ruxolitinib—JAK2—endometrium—breast cancer	0.000299	0.0026	CbGeAlD
Ruxolitinib—MKNK2—uterus—breast cancer	0.000299	0.0026	CbGeAlD
Ruxolitinib—LRRK2—adrenal gland—breast cancer	0.000298	0.0026	CbGeAlD
Ruxolitinib—TYK2—pituitary gland—breast cancer	0.000297	0.00259	CbGeAlD
Ruxolitinib—TYK2—adipose tissue—breast cancer	0.000296	0.00258	CbGeAlD
Ruxolitinib—CAMK1—lymph node—breast cancer	0.000293	0.00256	CbGeAlD
Ruxolitinib—MKNK2—pituitary gland—breast cancer	0.000293	0.00256	CbGeAlD
Ruxolitinib—DYRK1A—endocrine gland—breast cancer	0.000292	0.00255	CbGeAlD
Ruxolitinib—MKNK2—adipose tissue—breast cancer	0.000292	0.00255	CbGeAlD
Ruxolitinib—IRAK1—adipose tissue—breast cancer	0.000292	0.00255	CbGeAlD
Ruxolitinib—BMPR2—endocrine gland—breast cancer	0.000291	0.00254	CbGeAlD
Ruxolitinib—CAMK2G—bone marrow—breast cancer	0.000291	0.00253	CbGeAlD
Ruxolitinib—BMP2K—bone marrow—breast cancer	0.000291	0.00253	CbGeAlD
Ruxolitinib—LRRK2—bone marrow—breast cancer	0.000288	0.00251	CbGeAlD
Ruxolitinib—MAP3K3—endometrium—breast cancer	0.000288	0.00251	CbGeAlD
Ruxolitinib—RET—pituitary gland—breast cancer	0.000286	0.00249	CbGeAlD
Ruxolitinib—MARK2—lymph node—breast cancer	0.000285	0.00248	CbGeAlD
Ruxolitinib—BMP2K—female gonad—breast cancer	0.00028	0.00244	CbGeAlD
Ruxolitinib—CAMK2G—female gonad—breast cancer	0.00028	0.00244	CbGeAlD
Ruxolitinib—MAP3K2—female reproductive system—breast cancer	0.00028	0.00244	CbGeAlD
Ruxolitinib—LRRK2—female gonad—breast cancer	0.000278	0.00242	CbGeAlD
Ruxolitinib—MAP3K2—adrenal gland—breast cancer	0.000273	0.00238	CbGeAlD
Ruxolitinib—TYK2—female reproductive system—breast cancer	0.000272	0.00237	CbGeAlD
Ruxolitinib—JAK2—pituitary gland—breast cancer	0.00027	0.00236	CbGeAlD
Ruxolitinib—MAP3K7—adrenal gland—breast cancer	0.00027	0.00236	CbGeAlD
Ruxolitinib—JAK2—adipose tissue—breast cancer	0.000269	0.00235	CbGeAlD
Ruxolitinib—MKNK2—female reproductive system—breast cancer	0.000269	0.00234	CbGeAlD
Ruxolitinib—IRAK1—female reproductive system—breast cancer	0.000269	0.00234	CbGeAlD
Ruxolitinib—TYK2—adrenal gland—breast cancer	0.000266	0.00231	CbGeAlD
Ruxolitinib—MAP3K2—bone marrow—breast cancer	0.000264	0.0023	CbGeAlD
Ruxolitinib—TAOK2—lymph node—breast cancer	0.000264	0.0023	CbGeAlD
Ruxolitinib—TAOK3—endometrium—breast cancer	0.000263	0.00229	CbGeAlD
Ruxolitinib—IRAK1—adrenal gland—breast cancer	0.000262	0.00228	CbGeAlD
Ruxolitinib—MKNK2—adrenal gland—breast cancer	0.000262	0.00228	CbGeAlD
Ruxolitinib—MAP3K7—bone marrow—breast cancer	0.000262	0.00228	CbGeAlD
Ruxolitinib—CAMK2G—endocrine gland—breast cancer	0.000261	0.00227	CbGeAlD
Ruxolitinib—BMP2K—endocrine gland—breast cancer	0.000261	0.00227	CbGeAlD
Ruxolitinib—MAP3K3—pituitary gland—breast cancer	0.000261	0.00227	CbGeAlD
Ruxolitinib—MAP3K3—adipose tissue—breast cancer	0.00026	0.00226	CbGeAlD
Ruxolitinib—PLK4—Topotecan—Irinotecan—breast cancer	0.000258	0.066	CbGdCrCtD
Ruxolitinib—PLK1—Topotecan—Irinotecan—breast cancer	0.000258	0.066	CbGdCrCtD
Ruxolitinib—LRRK2—endocrine gland—breast cancer	0.000258	0.00225	CbGeAlD
Ruxolitinib—TYK2—bone marrow—breast cancer	0.000257	0.00224	CbGeAlD
Ruxolitinib—RET—adrenal gland—breast cancer	0.000256	0.00223	CbGeAlD
Ruxolitinib—MAP3K2—female gonad—breast cancer	0.000255	0.00222	CbGeAlD
Ruxolitinib—MKNK2—bone marrow—breast cancer	0.000254	0.00221	CbGeAlD
Ruxolitinib—IRAK1—bone marrow—breast cancer	0.000254	0.00221	CbGeAlD
Ruxolitinib—MAP3K7—female gonad—breast cancer	0.000252	0.0022	CbGeAlD
Ruxolitinib—TYK2—female gonad—breast cancer	0.000248	0.00216	CbGeAlD
Ruxolitinib—JAK2—female reproductive system—breast cancer	0.000248	0.00216	CbGeAlD
Ruxolitinib—MKNK2—female gonad—breast cancer	0.000244	0.00213	CbGeAlD
Ruxolitinib—IRAK1—female gonad—breast cancer	0.000244	0.00213	CbGeAlD
Ruxolitinib—JAK3—lymph node—breast cancer	0.000242	0.00211	CbGeAlD
Ruxolitinib—TAOK3—uterus—breast cancer	0.000242	0.00211	CbGeAlD
Ruxolitinib—JAK2—adrenal gland—breast cancer	0.000242	0.0021	CbGeAlD
Ruxolitinib—DCLK1—lymph node—breast cancer	0.000241	0.0021	CbGeAlD
Ruxolitinib—JAK1—lymph node—breast cancer	0.000241	0.0021	CbGeAlD
Ruxolitinib—PLK4—lymph node—breast cancer	0.000239	0.00208	CbGeAlD
Ruxolitinib—MAP3K3—female reproductive system—breast cancer	0.000239	0.00208	CbGeAlD
Ruxolitinib—TAOK3—pituitary gland—breast cancer	0.000238	0.00207	CbGeAlD
Ruxolitinib—MAP3K2—endocrine gland—breast cancer	0.000237	0.00206	CbGeAlD
Ruxolitinib—TAOK3—adipose tissue—breast cancer	0.000237	0.00206	CbGeAlD
Ruxolitinib—CAMK1D—lymph node—breast cancer	0.000235	0.00205	CbGeAlD
Ruxolitinib—JAK2—bone marrow—breast cancer	0.000234	0.00204	CbGeAlD
Ruxolitinib—PHKG2—lymph node—breast cancer	0.000234	0.00203	CbGeAlD
Ruxolitinib—MAP3K3—adrenal gland—breast cancer	0.000233	0.00203	CbGeAlD
Ruxolitinib—TYK2—endocrine gland—breast cancer	0.00023	0.00201	CbGeAlD
Ruxolitinib—DAPK2—lymph node—breast cancer	0.00023	0.002	CbGeAlD
Ruxolitinib—MKNK2—endocrine gland—breast cancer	0.000227	0.00198	CbGeAlD
Ruxolitinib—STK16—lymph node—breast cancer	0.000226	0.00197	CbGeAlD
Ruxolitinib—JAK2—female gonad—breast cancer	0.000225	0.00196	CbGeAlD
Ruxolitinib—MAP3K3—bone marrow—breast cancer	0.000225	0.00196	CbGeAlD
Ruxolitinib—HIPK2—lymph node—breast cancer	0.000225	0.00196	CbGeAlD
Ruxolitinib—RET—endocrine gland—breast cancer	0.000222	0.00193	CbGeAlD
Ruxolitinib—TAOK3—female reproductive system—breast cancer	0.000218	0.00189	CbGeAlD
Ruxolitinib—MAP3K3—female gonad—breast cancer	0.000217	0.00189	CbGeAlD
Ruxolitinib—DAPK3—lymph node—breast cancer	0.000216	0.00188	CbGeAlD
Ruxolitinib—CLK2—lymph node—breast cancer	0.000214	0.00186	CbGeAlD
Ruxolitinib—TAOK3—adrenal gland—breast cancer	0.000212	0.00185	CbGeAlD
Ruxolitinib—JAK2—endocrine gland—breast cancer	0.00021	0.00182	CbGeAlD
Ruxolitinib—TAOK3—bone marrow—breast cancer	0.000205	0.00179	CbGeAlD
Ruxolitinib—DYRK1A—lymph node—breast cancer	0.000202	0.00176	CbGeAlD
Ruxolitinib—MAP3K3—endocrine gland—breast cancer	0.000202	0.00176	CbGeAlD
Ruxolitinib—BMPR2—lymph node—breast cancer	0.000201	0.00175	CbGeAlD
Ruxolitinib—TAOK3—female gonad—breast cancer	0.000198	0.00172	CbGeAlD
Ruxolitinib—DYRK1A—Epirubicin—Idarubicin—breast cancer	0.000194	0.0495	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Idarubicin—breast cancer	0.000194	0.0495	CbGdCrCtD
Ruxolitinib—DYRK1A—Doxorubicin—Idarubicin—breast cancer	0.000194	0.0495	CbGdCrCtD
Ruxolitinib—NUAK2—lymph node—breast cancer	0.000192	0.00168	CbGeAlD
Ruxolitinib—TAOK3—endocrine gland—breast cancer	0.000184	0.0016	CbGeAlD
Ruxolitinib—CAMK2G—lymph node—breast cancer	0.00018	0.00157	CbGeAlD
Ruxolitinib—BMP2K—lymph node—breast cancer	0.00018	0.00157	CbGeAlD
Ruxolitinib—LRRK2—lymph node—breast cancer	0.000179	0.00156	CbGeAlD
Ruxolitinib—CAMK2G—Azacitidine—Gemcitabine—breast cancer	0.000166	0.0423	CbGdCrCtD
Ruxolitinib—MAP3K2—lymph node—breast cancer	0.000164	0.00143	CbGeAlD
Ruxolitinib—MAP3K7—lymph node—breast cancer	0.000162	0.00141	CbGeAlD
Ruxolitinib—Dizziness—Raloxifene—breast cancer	0.00016	0.00121	CcSEcCtD
Ruxolitinib—Headache—Anastrozole—breast cancer	0.00016	0.00121	CcSEcCtD
Ruxolitinib—Headache—Letrozole—breast cancer	0.00016	0.00121	CcSEcCtD
Ruxolitinib—Weight decreased—Paclitaxel—breast cancer	0.00016	0.00121	CcSEcCtD
Ruxolitinib—TYK2—lymph node—breast cancer	0.000159	0.00139	CbGeAlD
Ruxolitinib—Infestation NOS—Paclitaxel—breast cancer	0.000158	0.00119	CcSEcCtD
Ruxolitinib—Infestation—Paclitaxel—breast cancer	0.000158	0.00119	CcSEcCtD
Ruxolitinib—MKNK2—lymph node—breast cancer	0.000157	0.00137	CbGeAlD
Ruxolitinib—IRAK1—lymph node—breast cancer	0.000157	0.00137	CbGeAlD
Ruxolitinib—Bone pain—Doxorubicin—breast cancer	0.000156	0.00117	CcSEcCtD
Ruxolitinib—Body temperature increased—Chlorambucil—breast cancer	0.000155	0.00117	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—breast cancer	0.000155	0.00117	CcSEcCtD
Ruxolitinib—RET—lymph node—breast cancer	0.000153	0.00133	CbGeAlD
Ruxolitinib—Urinary tract infection—Paclitaxel—breast cancer	0.000153	0.00116	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Docetaxel—breast cancer	0.000153	0.00115	CcSEcCtD
Ruxolitinib—Headache—Raloxifene—breast cancer	0.000152	0.00115	CcSEcCtD
Ruxolitinib—Headache—Idarubicin—breast cancer	0.000152	0.00115	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Tamoxifen—breast cancer	0.000151	0.00114	CcSEcCtD
Ruxolitinib—Fatigue—Tamoxifen—breast cancer	0.000151	0.00114	CcSEcCtD
Ruxolitinib—Haematuria—Paclitaxel—breast cancer	0.00015	0.00113	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Paclitaxel—breast cancer	0.000149	0.00112	CcSEcCtD
Ruxolitinib—Flatulence—Irinotecan—breast cancer	0.000149	0.00112	CcSEcCtD
Ruxolitinib—Epistaxis—Paclitaxel—breast cancer	0.000149	0.00112	CcSEcCtD
Ruxolitinib—Infection—Vinorelbine—breast cancer	0.000148	0.00112	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Capecitabine—breast cancer	0.000148	0.00112	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—breast cancer	0.000148	0.00112	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Melphalan—breast cancer	0.000148	0.00111	CcSEcCtD
Ruxolitinib—Fatigue—Melphalan—breast cancer	0.000148	0.00111	CcSEcCtD
Ruxolitinib—Nervous system disorder—Vinorelbine—breast cancer	0.000147	0.00111	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Vinorelbine—breast cancer	0.000146	0.0011	CcSEcCtD
Ruxolitinib—Skin disorder—Vinorelbine—breast cancer	0.000145	0.0011	CcSEcCtD
Ruxolitinib—JAK2—lymph node—breast cancer	0.000145	0.00126	CbGeAlD
Ruxolitinib—Fatigue—Goserelin—breast cancer	0.000144	0.00109	CcSEcCtD
Ruxolitinib—Pancytopenia—Docetaxel—breast cancer	0.000142	0.00107	CcSEcCtD
Ruxolitinib—Haemoglobin—Paclitaxel—breast cancer	0.000142	0.00107	CcSEcCtD
Ruxolitinib—Infection—Thiotepa—breast cancer	0.000142	0.00107	CcSEcCtD
Ruxolitinib—Haemorrhage—Paclitaxel—breast cancer	0.000142	0.00107	CcSEcCtD
Ruxolitinib—Asthenia—Chlorambucil—breast cancer	0.000141	0.00106	CcSEcCtD
Ruxolitinib—Neutropenia—Docetaxel—breast cancer	0.00014	0.00106	CcSEcCtD
Ruxolitinib—Nervous system disorder—Thiotepa—breast cancer	0.00014	0.00106	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Thiotepa—breast cancer	0.00014	0.00105	CcSEcCtD
Ruxolitinib—Anaemia—Mitoxantrone—breast cancer	0.00014	0.00105	CcSEcCtD
Ruxolitinib—Anaemia—Irinotecan—breast cancer	0.00014	0.00105	CcSEcCtD
Ruxolitinib—MAP3K3—lymph node—breast cancer	0.00014	0.00122	CbGeAlD
Ruxolitinib—Pruritus—Chlorambucil—breast cancer	0.000139	0.00105	CcSEcCtD
Ruxolitinib—Skin disorder—Thiotepa—breast cancer	0.000139	0.00105	CcSEcCtD
Ruxolitinib—Pancytopenia—Capecitabine—breast cancer	0.000138	0.00104	CcSEcCtD
Ruxolitinib—Weight increased—Docetaxel—breast cancer	0.000136	0.00103	CcSEcCtD
Ruxolitinib—Anaemia—Gemcitabine—breast cancer	0.000136	0.00103	CcSEcCtD
Ruxolitinib—Neutropenia—Capecitabine—breast cancer	0.000136	0.00102	CcSEcCtD
Ruxolitinib—Weight decreased—Docetaxel—breast cancer	0.000136	0.00102	CcSEcCtD
Ruxolitinib—Anaemia—Fluorouracil—breast cancer	0.000134	0.00101	CcSEcCtD
Ruxolitinib—Infestation—Docetaxel—breast cancer	0.000134	0.00101	CcSEcCtD
Ruxolitinib—Infestation NOS—Docetaxel—breast cancer	0.000134	0.00101	CcSEcCtD
Ruxolitinib—PLK4—Epirubicin—Idarubicin—breast cancer	0.000132	0.0338	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Idarubicin—breast cancer	0.000132	0.0338	CbGdCrCtD
Ruxolitinib—PLK4—Doxorubicin—Idarubicin—breast cancer	0.000132	0.0338	CbGdCrCtD
Ruxolitinib—PLK1—Epirubicin—Idarubicin—breast cancer	0.000132	0.0338	CbGdCrCtD
Ruxolitinib—PLK1—Doxorubicin—Idarubicin—breast cancer	0.000132	0.0338	CbGdCrCtD
Ruxolitinib—Weight increased—Capecitabine—breast cancer	0.000132	0.000996	CcSEcCtD
Ruxolitinib—Body temperature increased—Goserelin—breast cancer	0.000132	0.000995	CcSEcCtD
Ruxolitinib—Weight decreased—Capecitabine—breast cancer	0.000131	0.00099	CcSEcCtD
Ruxolitinib—Infestation—Capecitabine—breast cancer	0.000129	0.000976	CcSEcCtD
Ruxolitinib—Infestation NOS—Capecitabine—breast cancer	0.000129	0.000976	CcSEcCtD
Ruxolitinib—Asthenia—Vinblastine—breast cancer	0.000129	0.000974	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Vinorelbine—breast cancer	0.000129	0.000974	CcSEcCtD
Ruxolitinib—Fatigue—Vinorelbine—breast cancer	0.000129	0.000972	CcSEcCtD
Ruxolitinib—TAOK3—lymph node—breast cancer	0.000127	0.00111	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Docetaxel—breast cancer	0.000126	0.000953	CcSEcCtD
Ruxolitinib—Epistaxis—Docetaxel—breast cancer	0.000126	0.000951	CcSEcCtD
Ruxolitinib—Urinary tract infection—Capecitabine—breast cancer	0.000126	0.000949	CcSEcCtD
Ruxolitinib—Asthenia—Tamoxifen—breast cancer	0.000125	0.000946	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—breast cancer	0.000124	0.000938	CcSEcCtD
Ruxolitinib—Pruritus—Tamoxifen—breast cancer	0.000124	0.000933	CcSEcCtD
Ruxolitinib—Haematuria—Capecitabine—breast cancer	0.000123	0.00093	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Thiotepa—breast cancer	0.000123	0.00093	CcSEcCtD
Ruxolitinib—Malnutrition—Paclitaxel—breast cancer	0.000123	0.000929	CcSEcCtD
Ruxolitinib—Fatigue—Thiotepa—breast cancer	0.000123	0.000928	CcSEcCtD
Ruxolitinib—Asthenia—Melphalan—breast cancer	0.000123	0.000926	CcSEcCtD
Ruxolitinib—Infection—Mitoxantrone—breast cancer	0.000122	0.000924	CcSEcCtD
Ruxolitinib—Infection—Irinotecan—breast cancer	0.000122	0.000924	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Capecitabine—breast cancer	0.000122	0.000923	CcSEcCtD
Ruxolitinib—Epistaxis—Capecitabine—breast cancer	0.000122	0.00092	CcSEcCtD
Ruxolitinib—Flatulence—Paclitaxel—breast cancer	0.000121	0.000916	CcSEcCtD
Ruxolitinib—Pruritus—Melphalan—breast cancer	0.000121	0.000913	CcSEcCtD
Ruxolitinib—Nervous system disorder—Irinotecan—breast cancer	0.000121	0.000912	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Mitoxantrone—breast cancer	0.000121	0.000911	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Irinotecan—breast cancer	0.000121	0.000911	CcSEcCtD
Ruxolitinib—Haemoglobin—Docetaxel—breast cancer	0.000121	0.000909	CcSEcCtD
Ruxolitinib—Haemorrhage—Docetaxel—breast cancer	0.00012	0.000905	CcSEcCtD
Ruxolitinib—Asthenia—Goserelin—breast cancer	0.00012	0.000903	CcSEcCtD
Ruxolitinib—Skin disorder—Mitoxantrone—breast cancer	0.00012	0.000903	CcSEcCtD
Ruxolitinib—Infection—Gemcitabine—breast cancer	0.000119	0.0009	CcSEcCtD
Ruxolitinib—Dizziness—Vinblastine—breast cancer	0.000119	0.000897	CcSEcCtD
Ruxolitinib—Body temperature increased—Vinorelbine—breast cancer	0.000118	0.000891	CcSEcCtD
Ruxolitinib—Pruritus—Goserelin—breast cancer	0.000118	0.000891	CcSEcCtD
Ruxolitinib—Nervous system disorder—Gemcitabine—breast cancer	0.000118	0.000888	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Gemcitabine—breast cancer	0.000118	0.000887	CcSEcCtD
Ruxolitinib—Infection—Fluorouracil—breast cancer	0.000117	0.000885	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Epirubicin—breast cancer	0.000117	0.000882	CcSEcCtD
Ruxolitinib—Haemoglobin—Capecitabine—breast cancer	0.000117	0.000881	CcSEcCtD
Ruxolitinib—Skin disorder—Gemcitabine—breast cancer	0.000117	0.00088	CcSEcCtD
Ruxolitinib—Haemorrhage—Capecitabine—breast cancer	0.000116	0.000876	CcSEcCtD
Ruxolitinib—Nervous system disorder—Fluorouracil—breast cancer	0.000116	0.000873	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Fluorouracil—breast cancer	0.000116	0.000872	CcSEcCtD
Ruxolitinib—Dizziness—Tamoxifen—breast cancer	0.000116	0.000872	CcSEcCtD
Ruxolitinib—Anaemia—Paclitaxel—breast cancer	0.000114	0.000859	CcSEcCtD
Ruxolitinib—Body temperature increased—Thiotepa—breast cancer	0.000113	0.000851	CcSEcCtD
Ruxolitinib—Headache—Vinblastine—breast cancer	0.000113	0.00085	CcSEcCtD
Ruxolitinib—Dizziness—Goserelin—breast cancer	0.00011	0.000833	CcSEcCtD
Ruxolitinib—Headache—Tamoxifen—breast cancer	0.000109	0.000826	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Doxorubicin—breast cancer	0.000108	0.000816	CcSEcCtD
Ruxolitinib—Asthenia—Vinorelbine—breast cancer	0.000107	0.000809	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Irinotecan—breast cancer	0.000106	0.000803	CcSEcCtD
Ruxolitinib—Fatigue—Mitoxantrone—breast cancer	0.000106	0.000802	CcSEcCtD
Ruxolitinib—Fatigue—Irinotecan—breast cancer	0.000106	0.000802	CcSEcCtD
Ruxolitinib—Pruritus—Vinorelbine—breast cancer	0.000106	0.000798	CcSEcCtD
Ruxolitinib—Headache—Goserelin—breast cancer	0.000105	0.000789	CcSEcCtD
Ruxolitinib—Malnutrition—Docetaxel—breast cancer	0.000104	0.000788	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—breast cancer	0.000104	0.000786	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Gemcitabine—breast cancer	0.000104	0.000782	CcSEcCtD
Ruxolitinib—Fatigue—Gemcitabine—breast cancer	0.000104	0.000781	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Epirubicin—breast cancer	0.000103	0.000778	CcSEcCtD
Ruxolitinib—Pancytopenia—Methotrexate—breast cancer	0.000103	0.000774	CcSEcCtD
Ruxolitinib—Asthenia—Thiotepa—breast cancer	0.000102	0.000773	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Fluorouracil—breast cancer	0.000102	0.000769	CcSEcCtD
Ruxolitinib—Malnutrition—Capecitabine—breast cancer	0.000101	0.000763	CcSEcCtD
Ruxolitinib—Neutropenia—Methotrexate—breast cancer	0.000101	0.000762	CcSEcCtD
Ruxolitinib—Pruritus—Thiotepa—breast cancer	0.000101	0.000762	CcSEcCtD
Ruxolitinib—Infection—Paclitaxel—breast cancer	9.99e-05	0.000753	CcSEcCtD
Ruxolitinib—Flatulence—Capecitabine—breast cancer	9.96e-05	0.000751	CcSEcCtD
Ruxolitinib—Dizziness—Vinorelbine—breast cancer	9.88e-05	0.000746	CcSEcCtD
Ruxolitinib—Nervous system disorder—Paclitaxel—breast cancer	9.86e-05	0.000744	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Paclitaxel—breast cancer	9.84e-05	0.000743	CcSEcCtD
Ruxolitinib—Skin disorder—Paclitaxel—breast cancer	9.77e-05	0.000737	CcSEcCtD
Ruxolitinib—Body temperature increased—Irinotecan—breast cancer	9.75e-05	0.000735	CcSEcCtD
Ruxolitinib—Body temperature increased—Mitoxantrone—breast cancer	9.75e-05	0.000735	CcSEcCtD
Ruxolitinib—Anaemia—Docetaxel—breast cancer	9.65e-05	0.000728	CcSEcCtD
Ruxolitinib—Infestation—Methotrexate—breast cancer	9.63e-05	0.000726	CcSEcCtD
Ruxolitinib—Infestation NOS—Methotrexate—breast cancer	9.63e-05	0.000726	CcSEcCtD
Ruxolitinib—Pancytopenia—Epirubicin—breast cancer	9.6e-05	0.000724	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Doxorubicin—breast cancer	9.54e-05	0.00072	CcSEcCtD
Ruxolitinib—Body temperature increased—Gemcitabine—breast cancer	9.49e-05	0.000716	CcSEcCtD
Ruxolitinib—Neutropenia—Epirubicin—breast cancer	9.45e-05	0.000713	CcSEcCtD
Ruxolitinib—Dizziness—Thiotepa—breast cancer	9.44e-05	0.000712	CcSEcCtD
Ruxolitinib—Headache—Vinorelbine—breast cancer	9.36e-05	0.000706	CcSEcCtD
Ruxolitinib—Anaemia—Capecitabine—breast cancer	9.34e-05	0.000705	CcSEcCtD
Ruxolitinib—Body temperature increased—Fluorouracil—breast cancer	9.33e-05	0.000704	CcSEcCtD
Ruxolitinib—Weight increased—Epirubicin—breast cancer	9.2e-05	0.000694	CcSEcCtD
Ruxolitinib—Haematuria—Methotrexate—breast cancer	9.18e-05	0.000693	CcSEcCtD
Ruxolitinib—Weight decreased—Epirubicin—breast cancer	9.14e-05	0.00069	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Methotrexate—breast cancer	9.11e-05	0.000687	CcSEcCtD
Ruxolitinib—Epistaxis—Methotrexate—breast cancer	9.08e-05	0.000685	CcSEcCtD
Ruxolitinib—Infestation NOS—Epirubicin—breast cancer	9.01e-05	0.00068	CcSEcCtD
Ruxolitinib—Infestation—Epirubicin—breast cancer	9.01e-05	0.00068	CcSEcCtD
Ruxolitinib—Headache—Thiotepa—breast cancer	8.94e-05	0.000675	CcSEcCtD
Ruxolitinib—DYRK1A—Doxorubicin—Epirubicin—breast cancer	8.89e-05	0.0227	CbGdCrCtD
Ruxolitinib—DYRK1A—Idarubicin—Epirubicin—breast cancer	8.89e-05	0.0227	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Epirubicin—breast cancer	8.89e-05	0.0227	CbGdCrCtD
Ruxolitinib—Pancytopenia—Doxorubicin—breast cancer	8.88e-05	0.00067	CcSEcCtD
Ruxolitinib—Asthenia—Mitoxantrone—breast cancer	8.84e-05	0.000667	CcSEcCtD
Ruxolitinib—Asthenia—Irinotecan—breast cancer	8.84e-05	0.000667	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	8.83e-05	0.000666	CcSEcCtD
Ruxolitinib—Urinary tract infection—Epirubicin—breast cancer	8.76e-05	0.000661	CcSEcCtD
Ruxolitinib—Neutropenia—Doxorubicin—breast cancer	8.75e-05	0.00066	CcSEcCtD
Ruxolitinib—Haemoglobin—Methotrexate—breast cancer	8.69e-05	0.000655	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Paclitaxel—breast cancer	8.68e-05	0.000655	CcSEcCtD
Ruxolitinib—Fatigue—Paclitaxel—breast cancer	8.67e-05	0.000654	CcSEcCtD
Ruxolitinib—Haemorrhage—Methotrexate—breast cancer	8.65e-05	0.000652	CcSEcCtD
Ruxolitinib—Asthenia—Gemcitabine—breast cancer	8.62e-05	0.00065	CcSEcCtD
Ruxolitinib—Haematuria—Epirubicin—breast cancer	8.59e-05	0.000648	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	8.55e-05	0.000645	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Epirubicin—breast cancer	8.52e-05	0.000643	CcSEcCtD
Ruxolitinib—Weight increased—Doxorubicin—breast cancer	8.51e-05	0.000642	CcSEcCtD
Ruxolitinib—Epistaxis—Epirubicin—breast cancer	8.5e-05	0.000641	CcSEcCtD
Ruxolitinib—Pruritus—Gemcitabine—breast cancer	8.5e-05	0.000641	CcSEcCtD
Ruxolitinib—Infection—Docetaxel—breast cancer	8.47e-05	0.000639	CcSEcCtD
Ruxolitinib—Weight decreased—Doxorubicin—breast cancer	8.46e-05	0.000638	CcSEcCtD
Ruxolitinib—Nervous system disorder—Docetaxel—breast cancer	8.36e-05	0.00063	CcSEcCtD
Ruxolitinib—Pruritus—Fluorouracil—breast cancer	8.35e-05	0.00063	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Docetaxel—breast cancer	8.34e-05	0.000629	CcSEcCtD
Ruxolitinib—Infestation NOS—Doxorubicin—breast cancer	8.34e-05	0.000629	CcSEcCtD
Ruxolitinib—Infestation—Doxorubicin—breast cancer	8.34e-05	0.000629	CcSEcCtD
Ruxolitinib—Skin disorder—Docetaxel—breast cancer	8.28e-05	0.000624	CcSEcCtD
Ruxolitinib—DYRK1A—Idarubicin—Doxorubicin—breast cancer	8.23e-05	0.021	CbGdCrCtD
Ruxolitinib—DYRK1A—Epirubicin—Doxorubicin—breast cancer	8.23e-05	0.021	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Doxorubicin—breast cancer	8.23e-05	0.021	CbGdCrCtD
Ruxolitinib—Infection—Capecitabine—breast cancer	8.2e-05	0.000618	CcSEcCtD
Ruxolitinib—Dizziness—Irinotecan—breast cancer	8.15e-05	0.000615	CcSEcCtD
Ruxolitinib—Haemoglobin—Epirubicin—breast cancer	8.13e-05	0.000613	CcSEcCtD
Ruxolitinib—Urinary tract infection—Doxorubicin—breast cancer	8.11e-05	0.000611	CcSEcCtD
Ruxolitinib—Nervous system disorder—Capecitabine—breast cancer	8.09e-05	0.00061	CcSEcCtD
Ruxolitinib—Haemorrhage—Epirubicin—breast cancer	8.09e-05	0.00061	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Capecitabine—breast cancer	8.08e-05	0.000609	CcSEcCtD
Ruxolitinib—Skin disorder—Capecitabine—breast cancer	8.01e-05	0.000605	CcSEcCtD
Ruxolitinib—Haematuria—Doxorubicin—breast cancer	7.95e-05	0.0006	CcSEcCtD
Ruxolitinib—Body temperature increased—Paclitaxel—breast cancer	7.95e-05	0.0006	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Doxorubicin—breast cancer	7.89e-05	0.000595	CcSEcCtD
Ruxolitinib—Epistaxis—Doxorubicin—breast cancer	7.87e-05	0.000593	CcSEcCtD
Ruxolitinib—Dizziness—Fluorouracil—breast cancer	7.81e-05	0.000589	CcSEcCtD
Ruxolitinib—Headache—Mitoxantrone—breast cancer	7.72e-05	0.000583	CcSEcCtD
Ruxolitinib—Headache—Irinotecan—breast cancer	7.72e-05	0.000583	CcSEcCtD
Ruxolitinib—Malnutrition—Methotrexate—breast cancer	7.53e-05	0.000568	CcSEcCtD
Ruxolitinib—Haemoglobin—Doxorubicin—breast cancer	7.52e-05	0.000568	CcSEcCtD
Ruxolitinib—Headache—Gemcitabine—breast cancer	7.52e-05	0.000568	CcSEcCtD
Ruxolitinib—Haemorrhage—Doxorubicin—breast cancer	7.49e-05	0.000565	CcSEcCtD
Ruxolitinib—Headache—Fluorouracil—breast cancer	7.4e-05	0.000558	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Docetaxel—breast cancer	7.36e-05	0.000555	CcSEcCtD
Ruxolitinib—Fatigue—Docetaxel—breast cancer	7.35e-05	0.000554	CcSEcCtD
Ruxolitinib—Asthenia—Paclitaxel—breast cancer	7.21e-05	0.000544	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Capecitabine—breast cancer	7.12e-05	0.000537	CcSEcCtD
Ruxolitinib—Fatigue—Capecitabine—breast cancer	7.11e-05	0.000537	CcSEcCtD
Ruxolitinib—Pruritus—Paclitaxel—breast cancer	7.11e-05	0.000537	CcSEcCtD
Ruxolitinib—Malnutrition—Epirubicin—breast cancer	7.04e-05	0.000531	CcSEcCtD
Ruxolitinib—Anaemia—Methotrexate—breast cancer	6.96e-05	0.000525	CcSEcCtD
Ruxolitinib—Flatulence—Epirubicin—breast cancer	6.94e-05	0.000524	CcSEcCtD
Ruxolitinib—Body temperature increased—Docetaxel—breast cancer	6.74e-05	0.000508	CcSEcCtD
Ruxolitinib—Dizziness—Paclitaxel—breast cancer	6.65e-05	0.000502	CcSEcCtD
Ruxolitinib—CYP3A4—female reproductive system—breast cancer	6.61e-05	0.000576	CbGeAlD
Ruxolitinib—PLK1—Cytarabine—Gemcitabine—breast cancer	6.55e-05	0.0167	CbGdCrCtD
Ruxolitinib—Body temperature increased—Capecitabine—breast cancer	6.52e-05	0.000492	CcSEcCtD
Ruxolitinib—Malnutrition—Doxorubicin—breast cancer	6.52e-05	0.000492	CcSEcCtD
Ruxolitinib—Anaemia—Epirubicin—breast cancer	6.51e-05	0.000491	CcSEcCtD
Ruxolitinib—Flatulence—Doxorubicin—breast cancer	6.42e-05	0.000484	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	6.36e-05	0.00048	CcSEcCtD
Ruxolitinib—Headache—Paclitaxel—breast cancer	6.3e-05	0.000475	CcSEcCtD
Ruxolitinib—Asthenia—Docetaxel—breast cancer	6.11e-05	0.000461	CcSEcCtD
Ruxolitinib—Infection—Methotrexate—breast cancer	6.1e-05	0.00046	CcSEcCtD
Ruxolitinib—PLK4—Idarubicin—Epirubicin—breast cancer	6.08e-05	0.0155	CbGdCrCtD
Ruxolitinib—PLK1—Idarubicin—Epirubicin—breast cancer	6.08e-05	0.0155	CbGdCrCtD
Ruxolitinib—PLK1—Doxorubicin—Epirubicin—breast cancer	6.08e-05	0.0155	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Epirubicin—breast cancer	6.08e-05	0.0155	CbGdCrCtD
Ruxolitinib—PLK4—Doxorubicin—Epirubicin—breast cancer	6.08e-05	0.0155	CbGdCrCtD
Ruxolitinib—Pruritus—Docetaxel—breast cancer	6.03e-05	0.000455	CcSEcCtD
Ruxolitinib—Nervous system disorder—Methotrexate—breast cancer	6.02e-05	0.000454	CcSEcCtD
Ruxolitinib—Anaemia—Doxorubicin—breast cancer	6.02e-05	0.000454	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Methotrexate—breast cancer	6.01e-05	0.000454	CcSEcCtD
Ruxolitinib—Skin disorder—Methotrexate—breast cancer	5.97e-05	0.00045	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	5.95e-05	0.000449	CcSEcCtD
Ruxolitinib—Asthenia—Capecitabine—breast cancer	5.92e-05	0.000447	CcSEcCtD
Ruxolitinib—Pruritus—Capecitabine—breast cancer	5.84e-05	0.00044	CcSEcCtD
Ruxolitinib—Infection—Epirubicin—breast cancer	5.71e-05	0.000431	CcSEcCtD
Ruxolitinib—Nervous system disorder—Epirubicin—breast cancer	5.64e-05	0.000425	CcSEcCtD
Ruxolitinib—Dizziness—Docetaxel—breast cancer	5.64e-05	0.000425	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Epirubicin—breast cancer	5.63e-05	0.000425	CcSEcCtD
Ruxolitinib—PLK4—Epirubicin—Doxorubicin—breast cancer	5.62e-05	0.0144	CbGdCrCtD
Ruxolitinib—PLK1—Idarubicin—Doxorubicin—breast cancer	5.62e-05	0.0144	CbGdCrCtD
Ruxolitinib—PLK1—Epirubicin—Doxorubicin—breast cancer	5.62e-05	0.0144	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Doxorubicin—breast cancer	5.62e-05	0.0144	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Doxorubicin—breast cancer	5.62e-05	0.0144	CbGdCrCtD
Ruxolitinib—CYP3A4—endocrine gland—breast cancer	5.59e-05	0.000487	CbGeAlD
Ruxolitinib—Skin disorder—Epirubicin—breast cancer	5.58e-05	0.000421	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	5.51e-05	0.000416	CcSEcCtD
Ruxolitinib—Dizziness—Capecitabine—breast cancer	5.46e-05	0.000412	CcSEcCtD
Ruxolitinib—Headache—Docetaxel—breast cancer	5.34e-05	0.000403	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Methotrexate—breast cancer	5.3e-05	0.0004	CcSEcCtD
Ruxolitinib—Fatigue—Methotrexate—breast cancer	5.3e-05	0.000399	CcSEcCtD
Ruxolitinib—Infection—Doxorubicin—breast cancer	5.28e-05	0.000399	CcSEcCtD
Ruxolitinib—Nervous system disorder—Doxorubicin—breast cancer	5.22e-05	0.000393	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Doxorubicin—breast cancer	5.21e-05	0.000393	CcSEcCtD
Ruxolitinib—Headache—Capecitabine—breast cancer	5.17e-05	0.00039	CcSEcCtD
Ruxolitinib—Skin disorder—Doxorubicin—breast cancer	5.17e-05	0.00039	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Epirubicin—breast cancer	4.96e-05	0.000374	CcSEcCtD
Ruxolitinib—Fatigue—Epirubicin—breast cancer	4.96e-05	0.000374	CcSEcCtD
Ruxolitinib—Body temperature increased—Methotrexate—breast cancer	4.86e-05	0.000366	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Doxorubicin—breast cancer	4.59e-05	0.000346	CcSEcCtD
Ruxolitinib—Fatigue—Doxorubicin—breast cancer	4.59e-05	0.000346	CcSEcCtD
Ruxolitinib—Body temperature increased—Epirubicin—breast cancer	4.54e-05	0.000343	CcSEcCtD
Ruxolitinib—Asthenia—Methotrexate—breast cancer	4.41e-05	0.000332	CcSEcCtD
Ruxolitinib—Pruritus—Methotrexate—breast cancer	4.35e-05	0.000328	CcSEcCtD
Ruxolitinib—Body temperature increased—Doxorubicin—breast cancer	4.2e-05	0.000317	CcSEcCtD
Ruxolitinib—Asthenia—Epirubicin—breast cancer	4.12e-05	0.000311	CcSEcCtD
Ruxolitinib—Pruritus—Epirubicin—breast cancer	4.07e-05	0.000307	CcSEcCtD
Ruxolitinib—Dizziness—Methotrexate—breast cancer	4.06e-05	0.000306	CcSEcCtD
Ruxolitinib—Headache—Methotrexate—breast cancer	3.85e-05	0.00029	CcSEcCtD
Ruxolitinib—Asthenia—Doxorubicin—breast cancer	3.82e-05	0.000288	CcSEcCtD
Ruxolitinib—Dizziness—Epirubicin—breast cancer	3.8e-05	0.000287	CcSEcCtD
Ruxolitinib—Pruritus—Doxorubicin—breast cancer	3.76e-05	0.000284	CcSEcCtD
Ruxolitinib—Headache—Epirubicin—breast cancer	3.6e-05	0.000272	CcSEcCtD
Ruxolitinib—Dizziness—Doxorubicin—breast cancer	3.52e-05	0.000265	CcSEcCtD
Ruxolitinib—Headache—Doxorubicin—breast cancer	3.33e-05	0.000251	CcSEcCtD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CG—breast cancer	6.96e-07	3.35e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APC—breast cancer	6.96e-07	3.35e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MAPK3—breast cancer	6.93e-07	3.34e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ERBB2—breast cancer	6.92e-07	3.33e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTA4—breast cancer	6.9e-07	3.32e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CA9—breast cancer	6.9e-07	3.32e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGF—breast cancer	6.88e-07	3.32e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MYC—breast cancer	6.85e-07	3.3e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PIK3CA—breast cancer	6.84e-07	3.29e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TGFB1—breast cancer	6.83e-07	3.29e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MTOR—breast cancer	6.83e-07	3.29e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CB—breast cancer	6.83e-07	3.29e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CDKN1B—breast cancer	6.81e-07	3.28e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—AKT1—breast cancer	6.78e-07	3.27e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CXCL8—breast cancer	6.77e-07	3.26e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PIK3CA—breast cancer	6.76e-07	3.25e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CTNNB1—breast cancer	6.76e-07	3.25e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MYC—breast cancer	6.74e-07	3.24e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTA2—breast cancer	6.73e-07	3.24e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GPX2—breast cancer	6.73e-07	3.24e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HRAS—breast cancer	6.72e-07	3.24e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TGFB1—breast cancer	6.72e-07	3.24e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EGFR—breast cancer	6.7e-07	3.23e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—KRAS—breast cancer	6.67e-07	3.21e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CASP3—breast cancer	6.67e-07	3.21e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—MAPK3—breast cancer	6.67e-07	3.21e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL2—breast cancer	6.66e-07	3.21e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GPX4—breast cancer	6.65e-07	3.2e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SULT1A1—breast cancer	6.65e-07	3.2e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PIK3CA—breast cancer	6.64e-07	3.2e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—SRC—breast cancer	6.61e-07	3.19e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CDKN1B—breast cancer	6.61e-07	3.18e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CDKN1A—breast cancer	6.6e-07	3.18e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EGFR—breast cancer	6.59e-07	3.17e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTEN—breast cancer	6.58e-07	3.17e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CXCL8—breast cancer	6.56e-07	3.16e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—BRAF—breast cancer	6.55e-07	3.15e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—AKT1—breast cancer	6.54e-07	3.15e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—breast cancer	6.54e-07	3.15e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCND1—breast cancer	6.49e-07	3.13e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTA1—breast cancer	6.49e-07	3.13e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—IDH1—breast cancer	6.49e-07	3.13e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—JUN—breast cancer	6.48e-07	3.12e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CASP3—breast cancer	6.48e-07	3.12e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL2—breast cancer	6.47e-07	3.11e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PIK3CA—breast cancer	6.44e-07	3.1e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL6—breast cancer	6.43e-07	3.1e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CTNNB1—breast cancer	6.43e-07	3.1e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NAT2—breast cancer	6.42e-07	3.09e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CDKN1B—breast cancer	6.41e-07	3.09e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—STAT3—breast cancer	6.38e-07	3.07e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IGF1—breast cancer	6.38e-07	3.07e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT2—breast cancer	6.37e-07	3.07e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—EGFR—breast cancer	6.34e-07	3.06e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KRAS—breast cancer	6.33e-07	3.05e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HRAS—breast cancer	6.33e-07	3.05e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MMP9—breast cancer	6.3e-07	3.04e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCND1—breast cancer	6.3e-07	3.04e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—JUN—breast cancer	6.29e-07	3.03e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CDKN1A—breast cancer	6.28e-07	3.03e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CASP3—breast cancer	6.28e-07	3.03e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL2—breast cancer	6.27e-07	3.02e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PTEN—breast cancer	6.27e-07	3.02e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HRAS—breast cancer	6.25e-07	3.01e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CTNNB1—breast cancer	6.24e-07	3.01e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KRAS—breast cancer	6.22e-07	3e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HRAS—breast cancer	6.14e-07	2.96e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK8—breast cancer	6.13e-07	2.95e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PIK3CA—breast cancer	6.13e-07	2.95e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CD—breast cancer	6.12e-07	2.95e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MMP9—breast cancer	6.12e-07	2.95e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCND1—breast cancer	6.11e-07	2.94e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—SRC—breast cancer	6.11e-07	2.94e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—JUN—breast cancer	6.1e-07	2.94e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CDKN1A—breast cancer	6.1e-07	2.94e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAPK3—breast cancer	6.09e-07	2.93e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PTEN—breast cancer	6.08e-07	2.93e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—PIK3CA—breast cancer	6.06e-07	2.92e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL6—breast cancer	6.06e-07	2.92e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SERPINE1—breast cancer	6.05e-07	2.92e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CTNNB1—breast cancer	6.05e-07	2.92e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—KRAS—breast cancer	5.99e-07	2.89e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL6—breast cancer	5.98e-07	2.88e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HRAS—breast cancer	5.96e-07	2.87e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK8—breast cancer	5.95e-07	2.87e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MMP9—breast cancer	5.94e-07	2.86e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—AKT1—breast cancer	5.94e-07	2.86e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CDKN1A—breast cancer	5.91e-07	2.85e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PTEN—breast cancer	5.9e-07	2.84e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—STAT3—breast cancer	5.89e-07	2.84e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL6—breast cancer	5.88e-07	2.83e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PIK3CA—breast cancer	5.81e-07	2.8e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SRC—breast cancer	5.81e-07	2.8e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EGFR—breast cancer	5.8e-07	2.79e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NOS3—breast cancer	5.78e-07	2.78e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK8—breast cancer	5.77e-07	2.78e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PIK3CA—breast cancer	5.72e-07	2.75e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL6—breast cancer	5.7e-07	2.75e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HRAS—breast cancer	5.67e-07	2.73e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—breast cancer	5.66e-07	2.73e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SRC—breast cancer	5.64e-07	2.72e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—DPYD—breast cancer	5.63e-07	2.71e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MED12—breast cancer	5.63e-07	2.71e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MAPK3—breast cancer	5.63e-07	2.71e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—breast cancer	5.62e-07	2.71e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—STAT3—breast cancer	5.6e-07	2.7e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—AKT1—breast cancer	5.59e-07	2.69e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALDOA—breast cancer	5.54e-07	2.67e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—breast cancer	5.53e-07	2.66e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—AKT1—breast cancer	5.52e-07	2.66e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PIK3CA—breast cancer	5.51e-07	2.65e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—breast cancer	5.5e-07	2.65e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MDM2—breast cancer	5.48e-07	2.64e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KRAS—breast cancer	5.48e-07	2.64e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SRC—breast cancer	5.47e-07	2.64e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MYC—breast cancer	5.47e-07	2.64e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—RAF1—breast cancer	5.47e-07	2.63e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TGFB1—breast cancer	5.46e-07	2.63e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—RELA—breast cancer	5.44e-07	2.62e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—STAT3—breast cancer	5.44e-07	2.62e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IL6—breast cancer	5.43e-07	2.61e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—AKT1—breast cancer	5.42e-07	2.61e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ERBB2—breast cancer	5.41e-07	2.6e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HRAS—breast cancer	5.38e-07	2.59e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NCOA3—breast cancer	5.38e-07	2.59e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK3—breast cancer	5.35e-07	2.58e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EGFR—breast cancer	5.35e-07	2.58e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC2A2—breast cancer	5.34e-07	2.57e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CB—breast cancer	5.34e-07	2.57e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MTOR—breast cancer	5.34e-07	2.57e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—breast cancer	5.33e-07	2.57e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HRAS—breast cancer	5.29e-07	2.55e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—STAT3—breast cancer	5.28e-07	2.54e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—AKT1—breast cancer	5.26e-07	2.53e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MTR—breast cancer	5.23e-07	2.52e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCG2—breast cancer	5.23e-07	2.52e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CPT1A—breast cancer	5.23e-07	2.52e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MYC—breast cancer	5.21e-07	2.51e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK3—breast cancer	5.2e-07	2.5e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TGFB1—breast cancer	5.2e-07	2.5e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL6—breast cancer	5.15e-07	2.48e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HPGDS—breast cancer	5.13e-07	2.47e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CXCL8—breast cancer	5.13e-07	2.47e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HBA1—breast cancer	5.1e-07	2.46e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HRAS—breast cancer	5.09e-07	2.45e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EGFR—breast cancer	5.09e-07	2.45e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL6—breast cancer	5.06e-07	2.44e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MYC—breast cancer	5.06e-07	2.44e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KRAS—breast cancer	5.06e-07	2.44e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TGFB1—breast cancer	5.04e-07	2.43e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK3—breast cancer	5.04e-07	2.43e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PIK3CA—breast cancer	5.03e-07	2.42e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDKN1B—breast cancer	5.01e-07	2.41e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—AKT1—breast cancer	5.01e-07	2.41e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ACHE—breast cancer	4.98e-07	2.4e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTT1—breast cancer	4.98e-07	2.4e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—AKT1—breast cancer	4.95e-07	2.39e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EGFR—breast cancer	4.95e-07	2.38e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CASP3—breast cancer	4.91e-07	2.36e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MYC—breast cancer	4.9e-07	2.36e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL2—breast cancer	4.9e-07	2.36e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TGFB1—breast cancer	4.89e-07	2.36e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL6—breast cancer	4.88e-07	2.35e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KRAS—breast cancer	4.81e-07	2.32e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EGFR—breast cancer	4.8e-07	2.31e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCND1—breast cancer	4.78e-07	2.3e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—JUN—breast cancer	4.77e-07	2.3e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—AKT1—breast cancer	4.75e-07	2.29e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CTNNB1—breast cancer	4.73e-07	2.28e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP17A1—breast cancer	4.71e-07	2.27e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KRAS—breast cancer	4.67e-07	2.25e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—AKT1—breast cancer	4.67e-07	2.25e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS1—breast cancer	4.66e-07	2.25e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ENO1—breast cancer	4.66e-07	2.25e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HRAS—breast cancer	4.65e-07	2.24e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CA—breast cancer	4.64e-07	2.24e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MMP9—breast cancer	4.64e-07	2.23e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDKN1A—breast cancer	4.62e-07	2.23e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTEN—breast cancer	4.61e-07	2.22e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP2D6—breast cancer	4.57e-07	2.2e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KRAS—breast cancer	4.53e-07	2.18e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK8—breast cancer	4.51e-07	2.17e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—AKT1—breast cancer	4.5e-07	2.17e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NCOA2—breast cancer	4.49e-07	2.16e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6—breast cancer	4.45e-07	2.15e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CA—breast cancer	4.42e-07	2.13e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—FASN—breast cancer	4.35e-07	2.1e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—BCHE—breast cancer	4.34e-07	2.09e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HRAS—breast cancer	4.3e-07	2.07e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CA—breast cancer	4.29e-07	2.07e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC5A5—breast cancer	4.28e-07	2.06e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—breast cancer	4.28e-07	2.06e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SRC—breast cancer	4.28e-07	2.06e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—breast cancer	4.16e-07	2.01e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CA—breast cancer	4.16e-07	2e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—breast cancer	4.15e-07	2e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC2A1—breast cancer	4.14e-07	1.99e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NQO1—breast cancer	4.14e-07	1.99e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—STAT3—breast cancer	4.12e-07	1.99e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6—breast cancer	4.11e-07	1.98e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—AKT1—breast cancer	4.11e-07	1.98e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HRAS—breast cancer	4.09e-07	1.97e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—breast cancer	4.03e-07	1.94e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HRAS—breast cancer	3.97e-07	1.91e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP1B1—breast cancer	3.97e-07	1.91e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK3—breast cancer	3.94e-07	1.9e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6—breast cancer	3.91e-07	1.89e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HSP90AA1—breast cancer	3.89e-07	1.87e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HRAS—breast cancer	3.85e-07	1.85e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MYC—breast cancer	3.83e-07	1.85e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TGFB1—breast cancer	3.82e-07	1.84e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6—breast cancer	3.8e-07	1.83e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—AKT1—breast cancer	3.79e-07	1.83e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NCOA1—breast cancer	3.78e-07	1.82e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGFR—breast cancer	3.75e-07	1.81e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP19A1—breast cancer	3.73e-07	1.8e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—STK11—breast cancer	3.73e-07	1.8e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6—breast cancer	3.69e-07	1.78e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AKT1—breast cancer	3.61e-07	1.74e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KRAS—breast cancer	3.54e-07	1.71e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AKT1—breast cancer	3.51e-07	1.69e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—COMT—breast cancer	3.47e-07	1.67e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTP1—breast cancer	3.45e-07	1.66e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HMOX1—breast cancer	3.4e-07	1.64e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AKT1—breast cancer	3.4e-07	1.64e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ITPR1—breast cancer	3.39e-07	1.63e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCB1—breast cancer	3.27e-07	1.57e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CA—breast cancer	3.25e-07	1.57e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TYMS—breast cancer	3.21e-07	1.54e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PLA2G4A—breast cancer	3.17e-07	1.53e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NCOR1—breast cancer	3.17e-07	1.53e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTM1—breast cancer	3.17e-07	1.53e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—breast cancer	3.15e-07	1.52e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GPX1—breast cancer	3.04e-07	1.46e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HRAS—breast cancer	3.01e-07	1.45e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP1A1—breast cancer	3e-07	1.45e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ERCC2—breast cancer	2.98e-07	1.44e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6—breast cancer	2.88e-07	1.39e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MTHFR—breast cancer	2.8e-07	1.35e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT1—breast cancer	2.66e-07	1.28e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CAV1—breast cancer	2.58e-07	1.24e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CG—breast cancer	2.35e-07	1.13e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CD—breast cancer	2.07e-07	9.97e-07	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALB—breast cancer	2.04e-07	9.84e-07	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NOS3—breast cancer	1.95e-07	9.41e-07	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CB—breast cancer	1.8e-07	8.69e-07	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—breast cancer	1.79e-07	8.61e-07	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTEN—breast cancer	1.56e-07	7.51e-07	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CA—breast cancer	1.1e-07	5.3e-07	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKT1—breast cancer	8.98e-08	4.33e-07	CbGpPWpGaD
